Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers

With several therapeutic strategies for facioscapulohumeral muscular dystrophy (FSHD) entering clinical testing, outcome measures are becoming increasingly important. Considering the spatiotemporal nature of FSHD disease activity, clinical trials would benefit from non-invasive imaging-based biomark...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Heuvel, Anita, Lassche, Saskia, Mul, Karlien, Greco, Anna, San León Granado, David, Heerschap, Arend, Küsters, Benno, Tapscott, Stephen J., Voermans, Nicol C., van Engelen, Baziel G. M., van der Maarel, Silvère M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791933/
https://www.ncbi.nlm.nih.gov/pubmed/35082321
http://dx.doi.org/10.1038/s41598-022-04817-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791933/
https://www.ncbi.nlm.nih.gov/pubmed/35082321
http://dx.doi.org/10.1038/s41598-022-04817-8

Ejemplares similares